Drug Profile
OCU 200
Alternative Names: OCU-200; Transferrin-TumstatinLatest Information Update: 11 May 2023
Price :
$50
*
At a glance
- Originator University of Colorado at Anschutz Medical Campus
- Developer Ocugen
- Class Eye disorder therapies; Recombinant fusion proteins
- Mechanism of Action Angiogenesis inhibitors; Integrin alphaVbeta3 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic macular oedema; Diabetic retinopathy; Wet age-related macular degeneration
Most Recent Events
- 30 Apr 2023 US FDA places clinical hold to an IND application of OCU 200 seeking additional information, in April 2023
- 27 Feb 2023 Ocugen files an IND application with the US FDA in the US for Diabetic macular oedema
- 27 Feb 2023 Ocugen plans a phase I trial for Diabetic macular oedema (Monotherapy, Combination therapy) (Intravitreous)